FDA Cites snusblast.co.uk in 2026-07-02 Warning Letter — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
Letter issued · posted to fda.gov .
Subject as published: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
TL;DR
Here's the summary: On July 2, 2026, the FDA Center for Tobacco Products issued a warning letter to snusblast.co.uk (MARCS-CMS 733425) finding that Zyn Chili Guava X-Strong Nicotine Pouches 11mg sold through the website's e-commerce platform were misbranded under the Family Smoking Prevention and Tobacco Control Act because an individual under 21 years of age purchased the product. The FDA determined the nicotine pouches are tobacco products subject to FDA jurisdiction and required the entity to submit a written response within 15 working days outlining corrective actions, warning that failure to comply may result in civil penalties, seizure, and injunction.
Argus analysis
# FDA Warning Letter Analysis: snusblast.co.uk
**Company and Violation**
Snusblast.co.uk, a United Kingdom-based online retailer, received a warning letter from the FDA's Center for Tobacco Products on July 2, 2026. The agency determined that the company sold nicotine pouch products—specifically Zyn Chili Guava X-Strong Nicotine Pouches (11mg)—to a person under 21 years of age through its website. The FDA classifies nicotine pouches as tobacco products under federal law because they contain nicotine derived from tobacco or other sources and are intended for human consumption, placing them under FDA jurisdiction regardless of the retailer's location.
**Regulatory Citations and Requirements**
The violation centers on 21 CFR § 1100.1 and section 906(d)(5) of the Federal Food, Drug, and Cosmetic Act, which establish that no tobacco retailer may sell tobacco products to anyone under 21. The warning letter also cites section 903(a)(7)(B), which deems products "misbranded" when sold in violation of age-restriction requirements. These provisions reflect FDA's authority over all tobacco products marketed to U.S. consumers, including those sold online from foreign domains. The regulations apply to labeling, advertising, and distribution across all platforms—websites, social media, and search engines.
**Response Timeline and Industry Watchpoints**
Snusblast.co.uk has 15 working days to submit a written response detailing corrective actions and compliance plans. Compliance officers monitoring this case should watch for FDA enforcement escalation if the company fails to respond adequately. The letter warns of potential civil money penalties, product seizure, and injunctions. The FDA copied Google and domain registrar Tucows, signaling coordinated pressure on payment processors and hosting platforms. Peers in e-commerce tobacco should note that operating from outside the U.S. does not shield retailers from FDA enforcement when products reach American consumers.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER snusblast.co.uk MARCS-CMS 733425 — July 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Tobacco Recipient: snusblast.co.uk United Kingdom info@snusblast.co.uk Issuing Office: Center for Tobacco Products United States July 2, 2026 WARNING LETTER To Whom It May Concern: The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed the website https://snusblast.co.uk and determined that nicotine pouch products listed there are offered for sale or distribution to consumers in the United States. Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source, and are intended for human consumption. 1 Certain tobacco products, including nicotine pouch products, are subject to FDA jurisdiction under section 901 of the FD&C Act (21 U.S.C. § 387a) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act. Under section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)), it is unlawful for any retailer 2 to sell a tobacco product to any person younger than 21 years of age. 3 This includes tobacco products containing nicotine from any source including cigarettes, smokeless tobacco, cigars, e-cigarettes, and nicotine pouches. Tobacco Product Sold by a Retailer to an Individual Under the Age of 21 is Misbranded Under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)), tobacco products are misbranded if sold or distributed by any retailer to a person younger than 21 years of age in violation of section 906(d)(5) of the FD&C Act (21 U.S.C. § 387f(d)(5)). FDA has determined that your Zyn Chili Guava X-Strong Nicotine Pouches 11mg nicotine pouch product is misbranded under section 903(a)(7)(B) of the FD&C Act (21 U.S.C. § 387c(a)(7)(B)) because this product was sold to a person younger than 21 years of age. Specifically, during FDA’s investigation of https://snusblast.co.uk, a person younger than 21 years of age purchased Zyn Chili Guava X-Strong Nicotine Pouches 11mg nicotine pouch product from your website. Conclusion and Requested Actions It is your responsibility to ensure that your tobacco products and all related labeling and/or advertising on this website, on any other websites (including e-commerce, social networking, or search engine websites), in any other media in which you advertise, and in any retail establishments comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq., and FDA’s implementing regulations, including those in 21 C.F.R. Parts 1140, 1141, and 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and/or injunction. Please note that tobacco products offe…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Tobacco / ENDS warning letter?
- Tobacco letters cite the Family Smoking Prevention and Tobacco Control Act, primarily Section 910 (premarket review of new tobacco products) for ENDS / e-vapor SKUs.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has snusblast.co.uk had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for snusblast.co.uk as of 2026-07-14. Argus ingests new FDA enforcement records daily.
- What FDA violations was snusblast.co.uk cited for?
- The FDA Warning Letter to snusblast.co.uk (issuing office: Center for Tobacco Products) cites: Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Classification: Tobacco / ENDS.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Cites snusblast.co.uk in 2026-07-02 Warning Letter — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-snusblast-co-uk-2026-07-02-tobacco
"FDA Cites snusblast.co.uk in 2026-07-02 Warning Letter — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-snusblast-co-uk-2026-07-02-tobacco.
Argus HQ Research. "FDA Cites snusblast.co.uk in 2026-07-02 Warning Letter — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded." Digital Empire LLC. Accessed July 15, 2026. https://argushq.ai/fda/warning-letter/fda-wl-snusblast-co-uk-2026-07-02-tobacco.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_snusblast_co_uk_2026_07_02_tobacco_2026,
title = {FDA Cites snusblast.co.uk in 2026-07-02 Warning Letter — Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-snusblast-co-uk-2026-07-02-tobacco},
note = {Accessed: July 15, 2026}
}